1 / 49

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010

Explore the evolving landscape of hematopoietic stem cell transplantation from 1980-2009, focusing on donor types, transplant activities, sources, and outcomes across different age groups in North America and globally.

robertksmith
Download Presentation

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation2010 CIBMTR Summary Slides SUM10_1.ppt

  2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Location of transplant centers participating in CIBMTR2008 . . . . . . . . . . . . . . . . . . . . . . . Slide 2 SUM10_2.ppt

  3. Transplant activity worldwide1980-2009 35,000 Autologous Allogeneic 30,000 25,000 20,000 Transplants 15,000 10,000 5,000 0 '80 '81 '82 '83 '84 '85 '86 '87 '88 '89 '90 '91 '92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 Slide 3 SUM10_3.ppt

  4. Transplant activity in the U.S.1980-2009 18,000 Autologous Related Donor Unrelated Donor 16,000 14,000 12,000 10,000 Transplants 8,000 6,000 4,000 2,000 0 '80 '81 '82 '83 '84 '85 '86 '87 '88 '89 '90 '91 '92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 Slide 4 SUM10_4.ppt

  5. Allogeneic stem cell sources,by recipient age1999-2008 100 Bone Marrow (BM) Peripheral Blood (PB) Cord Blood (CB) 80 60 Transplants, % 40 20 0 1999-2003 2004-2008 1999-2003 2004-2008 Age £20 yrs Age >20 yrs Slide 5 SUM10_7.ppt

  6. Autologous stem cell sources,by recipient age1999-2008 100 Bone Marrow (BM) Peripheral Blood (PB) BM + PB 80 60 Transplants, % 40 20 0 1999-2003 2004-2008 1999-2003 2004-2008 Age £20 yrs Age >20 yrs Slide 6 SUM10_8.ppt

  7. Trends in transplantation,by transplant type and recipient age*1999-2008 100 £ 20 yrs 21-40 yrs 41-50 yrs 51-60 yrs > 60 yrs 80 60 Transplants, % 40 20 0 1999-2003 2004-2008 1999-2003 2004-2008 Allogeneic Transplants Autologous Transplants * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 7 SUM10_9.ppt

  8. Trends in transplantation,by transplant type and recipient age*1999-2008 100 < 50 years < 60 years ³ 50 years ³ 60 years 80 60 Transplants, % 40 20 0 1988-1994 1995-2001 2002-2008 1988-1994 1995-2001 2002-2008 Allogeneic Transplants Autologous Transplants * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 8 SUM10_29.ppt

  9. Indications for hematopoietic stem cell transplant in North America2008 5,500 Allogeneic (Total N=6,672) 5,000 Autologous (Total N=10,302) 4,500 4,000 3,500 3,000 Number of Transplants 2,500 2,000 1,500 1,000 500 0 Multiple NHL AML HD ALL MDS/MPD Aplastic CML Other Other Non- Myeloma Anemia Leuk Cancer Malig Disease Slide 9 SUM10_11.ppt

  10. Indications for hematopoietic stem cell transplant for ages £20 years in North America2008 800 Allogeneic (Total N=1,496) 700 Autologous (Total N=880) 600 500 Number of Transplants Number of Transplants 400 300 200 100 0 Other ALL AML Aplastic HD NHL MDS/MPD CML Other Non- Cancer Anemia Leuk Malig Disease Slide 10 SUM10_12.ppt

  11. Indications for allogeneic hematopoietic stem cell transplantation in North America2008 3,000 Related Donor (Total N=3,282) Unrelated Donor (Total N=3,389) 2,500 2,000 Number of Transplants 1,500 1,000 500 0 AML ALL MDS/MPD NHL Aplastic CML Multiple HD Other Other Non- Anemia Myeloma Leuk Cancer Malig Disease Slide 11 SUM10_13.ppt

  12. Allogeneic transplants in patients £20 years,by donor type and graft source, registered with CIBMTR,1991-2008 5,000 Related, BM or PB Unrelated, BM or PB Unrelated, CB 4,500 4,000 3,500 3,000 Number of Transplants Number of Transplants 2,500 2,000 1,500 1,000 500 0 * * Data incomplete 1991-92 1993-94 1995-96 1997-98 1999-00 2001-02 2003-04 2005-06 2007-08 Slide 12 SUM10_14.ppt

  13. Allogeneic transplant in patients >20 years,by donor type and graft source, registered with CIBMTR, 1991-2008 13,000 12,000 Related, BM or PB Unrelated, BM Unrelated, PB Unrelated, CB 11,000 10,000 9,000 8,000 7,000 Number of Transplants Number of Transplants 6,000 5,000 4,000 3,000 2,000 1,000 0 * * Data incomplete 1991-92 1993-94 1995-96 1997-98 1999-00 2001-02 2003-04 2005-06 2007-08 Slide 13 SUM10_15.ppt

  14. Unrelated donor stem cell sourcesby recipient age1999-2008 100 Bone Marrow (BM) Peripheral Blood (PB) Cord Blood (CB) 80 60 Transplants, % 40 20 0 1999-2003 2004-2008 1999-2003 2004-2008 Age £20 yrs Age >20 yrs Slide 14 SUM10_16.ppt

  15. Unrelated cord blood transplantationregistered with CIBMTR1999-2008 800 ³ 16 years < 16 years 700 600 500 Number of Transplants Number of Transplants 400 300 200 100 0 * * * Data incomplete 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Slide 15 SUM10_17.ppt

  16. One-year survival after myeloablative conditioning for acute leukemias in any remission phase, CML or MDS, age <50 years, by year of transplant and graft source, 1988-2008 100 Sibling Donor Unrelated Donor 80 60 One-Year Survival, % 40 20 0 1988-90 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Slide 16 SUM10_18.ppt

  17. 100-day mortality after autologous transplantation2007-2008 15 Early Disease Intermediate/Advance Disease Sensitive Resistant Other 12 9 Mortality, % 6 3 0 Acute Leukemia Non-HodgkinLymphoma Hodgkin Disease MultipleMyeloma Slide 17 SUM10_19.ppt

  18. 100-day mortality after HLA-identical sibling transplantation2007-2008 100 Early Disease Intermediate Disease Advance Disease Chronic Phase Accelerated Phase Blast Phase Other 80 60 Mortality, % 40 20 0 AML ALL CML MDS/MPS AplasticAnemia Immune Deficiency Slide 18 SUM10_20.ppt

  19. 100-day mortality after unrelated donor transplantation2007-2008 100 Early Disease Intermediate Disease Advance Disease Chronic Phase Accelerated Phase Blast Phase Other 80 60 Mortality, % 40 20 0 AML ALL CML MDS/MPS AplasticAnemia Immune Deficiency Slide 19 SUM10_21.ppt

  20. Causes of death after transplantations done in 2003-2008 Autologous Primary Disease IPn * (1%) (73%) Infection (5%) Organ Failure (4%) Other Cause (17%) HLA-identical sibling Primary Disease (43%) GVHD (10%) Unrelated donor IPn * (3%) Primary Disease GVHD (12%) (35%) Infection (14%) IPn * (5%) Organ Failure (8%) Other (22%) Infection (17%) Other Cause (19%) *IPn = Idiopathic pneumonia syndrome Slide 20 Organ Failure (12%) SUM10_22.ppt

  21. Allogeneic transplantations by conditioning regimen intensity and patient age, registered with CIBMTR1999-2008 11,000 Reduced Intensity Conditioning, Age ³ 50 years Reduced Intensity Conditioning, Age < 50 years Standard Myeloablative Conditioning 10,000 9,000 8,000 7,000 6,000 Number of Transplants 5,000 4,000 3,000 2,000 1,000 0 * * * Data incomplete 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Slide 21 SUM10_23.ppt

  22. Allogeneic transplantations using reduced-intensity conditioning, by donor type, registered with CIBMTR1998-2008 3,000 Unrelated CB Unrelated PB/BM Related 2,500 2,000 Number of Transplants 1,500 1,000 500 0 * * * Data incomplete 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Slide 22 SUM10_24.ppt

  23. Number of allogeneic transplants, by disease, registered with CIBMTR 1998-2008 3,000 AML ALL CML AA LYM / MM / CLL 2,500 2,000 Transplants 1,500 1,000 500 0 * * * Data incomplete 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Slide 23 SUM10_25.ppt

  24. Number of allogeneic transplants for AML, by disease status, registered with CIBMTR1998-2008 1,400 Early Disease Intermediate Disease Advanced Disease 1,200 1,000 800 Transplants 600 400 200 0 * * * Data incomplete 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Slide 24 SUM10_26.ppt

  25. Number of allogeneic transplantations for ALL, by disease status, registered with CIBMTR 1998-2008 1,000 Early Disease Intermediate Disease Advanced Disease 800 600 Transplants 400 200 0 * * * Data incomplete 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Slide 25 SUM10_27.ppt

  26. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after HLA-matched sibling donor transplant for AML, by disease status, 1998-2008 Early (N=6,898) Probability of Survival, % Intermediate (N=1,805) Advanced (N=3,011) P < 0.0001 1 3 0 2 4 5 6 Years Slide 26 SUM10_32.ppt

  27. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after unrelated donor transplant for AML, by disease status, 1998-2008 Early (N=3,658) Probability of Survival, % Intermediate (N=2,774) Advanced (N=3,242) P < 0.0001 1 3 0 2 4 5 6 Years Slide 27 SUM10_33.ppt

  28. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after HLA-matched sibling donor transplant for AML, age <20 years, by disease status, 1998-2008 Early (N=1,384) Probability of Survival, % Intermediate (N=285) Advanced (N=309) P < 0.0001 1 3 0 2 4 5 6 Years Slide 28 SUM09_34.ppt

  29. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after HLA-matched sibling donor transplant for AML with reduced-intensity conditioning, by disease status, 1998-2008 Probability of Survival, % Early (N=1,129) Intermediate (N=377) Advanced (N=571) P < 0.0001 1 3 0 2 4 5 6 Years Slide 29 SUM10_35.ppt

  30. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after unrelated donor transplant for AML with reduced-intensity conditioning, by disease status, 1998-2008 Probability of Survival, % Early (N=951) Intermediate (N=585) Advanced (N=728) P < 0.0001 1 3 0 2 4 5 6 Years Slide 30 SUM10_36.ppt

  31. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after autologous transplant for AML, by disease status, 1998-2008 Probability of Survival, % Early (N=2,319) Intermediate (N=769) Advanced (N=221) P < 0.0001 1 3 0 2 4 5 6 Years Slide 31 SUM10_38.ppt

  32. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after allogeneic transplant for MDS, age <20 years, by disease status and donor type, 1998-2008 Early, unrelated (N=145) Early, HLA-matched sibling (N=63) Advanced, HLA-matched sibling (N=114) Probability of Survival, % Advanced, unrelated (N=190) P = 0.002 1 3 0 2 4 5 6 Years Slide 32 SUM10_39.ppt

  33. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after allogeneic transplant for MDS, age ³20 years, by disease status and donor type, 1998-2008 Early, unrelated (N=509) Early, HLA-matched sibling (N=599) Probability of Survival, % Advanced, unrelated (N=1,142) Advanced, HLA-matched sibling (N=1,237) P < 0.0001 1 3 0 2 4 5 6 Years Slide 33 SUM10_40.ppt

  34. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after allogeneic transplant for MDS with reduced-intensity conditioning, by disease status and donor type, 1998-2008 Advanced, HLA-matched sibling (N=366) Early, HLA-matched sibling (N=217) Probability of Survival, % Early, unrelated (N=202) Advanced, unrelated (N=383) P < 0.0001 1 3 0 2 4 5 6 Years Slide 34 SUM10_41.ppt

  35. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after HLA-matched sibling donor transplant for ALL, age <20 years, by disease status, 1998-2008 Early (N=915) Probability of Survival, % Intermediate (N=1,313) Advanced (N=243) P < 0.0001 1 3 0 2 4 5 6 Years Slide 35 SUM10_42.ppt

  36. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after unrelated donor transplant for ALL, age <20 years, by disease status, 1998-2008 Early (N=831) Probability of Survival, % Intermediate (N=2,041) Advanced (N=340) P < 0.0001 1 3 0 2 4 5 6 Years Slide 36 SUM10_43.ppt

  37. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after HLA-matched sibling donor transplant for ALL, age ³20 years, by disease status, 1998-2008 Probability of Survival, % Early (N=1,993) Intermediate (N=700) Advanced (N=716) P < 0.0001 1 3 0 2 4 5 6 Years Slide 37 SUM10_44.ppt

  38. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after unrelated donor transplant for ALL, age ³20 years, by disease status, 1998-2008 Probability of Survival, % Early (N=1,363) Intermediate (N=934) Advanced (N=784) P < 0.0001 1 3 0 2 4 5 6 Years Slide 38 SUM09_45.ppt

  39. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after HLA-matched sibling donor transplant for CML, by disease status and transplant year, 1998-2008 CP, 2001-2008 (N=2,412) CP, 1998-2000 (N=2,302) Probability of Survival, % AP, 2001-2008 (N=314) AP, 1998-2000 (N=301) P < 0.0001 1 3 0 2 4 5 6 Years Slide 39 SUM10_46.ppt

  40. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after autologous and HLA-matched sibling donor transplants for CLL, 1998-2008 autologous transplant (N=399) Probability of Survival, % Myeloablative conditioning(N=458) Reduced-intensity conditioning (N=679) P < 0.0001 1 3 0 2 4 5 6 Years Slide 40 SUM10_47.ppt

  41. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after allogeneic transplant for severe aplastic anemia, by donor type and age, 1998-2008 HLA-matched sibling, £20 y (N=1,388) HLA-matched sibling, >20 y (N=1,408) Unrelated, £20 y (N=562) Probability of Survival, % Unrelated, >20 y (N=532) P < 0.0001 1 3 0 2 4 5 6 Years Slide 41 SUM10_48.ppt

  42. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after autologous transplant for Hodgkin disease, by disease status, 1998-2008 Complete remission (N=2,437) Not in CR, sensitive (N=3,237) Probability of Survival, % Not in CR, resistant (N=699) P < 0.0001 1 3 0 2 4 5 6 Years Slide 42 SUM10_49.ppt

  43. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after allogeneic transplant for Hodgkin disease, by donor type and conditioning regimen, 1998-2008 Unrelated, reduced-intensity conditioning (N=110) HLA-matched sibling, myeloablative (N=190) HLA-matched sibling, reduced-intensity conditioning (N=153) Probability of Survival, % Unrelated, myeloablative (N=71) P = 0.021 1 3 0 2 4 5 6 Years Slide 43 SUM10_50.ppt

  44. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after autologous transplant for follicular lymphoma, by disease status, 2000-2008 Chemosensitive (N=1,995) Probability of Survival, % Chemoresistant (N=160) P < 0.0001 1 3 0 2 4 5 6 Years Slide 44 SUM10_51.ppt

  45. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after HLA-matched sibling donor allogeneic transplant for follicular lymphoma, by disease status and conditioning regimen, 1998-2008 Chemosensitive, reduced–intensity conditioning (N=388) Chemosensitive, myeloablative (N=351) Chemoresistant, reduced–intensity conditioning (N=64) Probability of Survival, % Chemoresistant, myeloablative (N=85) P = 0.011 1 3 0 2 4 5 6 Years Slide 45 SUM10_52.ppt

  46. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after autologous transplant for diffuse large B-cell lymphoma, by disease status, 2000-2008 Chemosensitive (N=6,203) Probability of Survival, % Chemoresistant (N=447) P < 0.0001 1 3 0 2 4 5 6 Years Slide 46 SUM10_53.ppt

  47. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after HLA-matched sibling donor allogeneic transplant for diffuse large B-cell lymphoma, by disease status and conditioning regimen, 1998-2008 Probability of Survival, % Chemosensitive, reduced-intensity conditioning (N=122) Chemosensitive, myeloablative (N=315) Chemoresistant, reduced-intensity conditioning (N=43) Chemoresistant, myeloablative (N=98) P < 0.0001 1 3 0 2 4 5 6 Years Slide 47 SUM10_54.ppt

  48. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after transplant for mantle cell lymphoma, by donor type and conditioning regimen, 1998-2008 HLA-matched sibling, reduced-intensity conditioning (N=229) HLA-matched sibling, myeloablative (N=284) autologous transplant (N=2,390) Probability of Survival, % Unrelated, myeloablative (N=94) Unrelated, reduced-intensity conditioning (N=184) P < 0.0001 1 3 0 2 4 5 6 Years Slide 48 SUM10_55.ppt

  49. 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 Probability of survival after transplant for multiple myeloma, by donor type1998-2008 autologous transplant (N=22,254) Probability of Survival, % HLA-matched sibling, Allo (N=878) Unrelated, Allo (N=143) P < 0.0001 1 3 0 2 4 5 6 Years Slide 49 SUM10_56.ppt

More Related